PET/CT Imaging for ATTR Gene Carriers
This study aims to find out if people who carry the TTR gene mutation, but don't yet have heart failure, show early signs of a heart condition called amyloidosis. Researchers will use a special imaging test called a PET/CT scan with a new dye called Iodine-124 Evuzamitide (I-124E). This dye helps make amyloid deposits visible in the heart and body. You may be able to join if you are between 30 and 80 years old, carry the TTR gene mutation, and do not have a history of heart failure. The main goal is to see how much of the dye is taken up by your heart during the PET/CT scan. The study is currently recruiting participants.
- Study design
- This is an observational study planning to enroll 80 participants, including TTR gene carriers, non-carrier controls, and patients with ATTR-CA.
- What's involved
- You will have a screening that includes a medical history review and quality-of-life surveys, followed by a PET/CT imaging test.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
PET/CT Imaging in Carriers of TTR Mutations
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Justin L Grodin, MD MPH · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- LV % Injected dosePET/CT Scan Visit
Evidence of subclinical cardiac amyloid infiltration as measured by PET/CT quantification imaging with I-124E. This will be defined as LV % injected dose (LV%ID = volume of interest \[VOI\] mean activity concentration in the LV X VOI volume / injected activity). LV%ID is an ideal metric to assess cardiac amyloid burden because it is: 1) correlated with validated metrics assessing cardiac amyloid burden; 2) sensitive for detection of early disease (patchy vs. diffuse uptake); and 3) highly repeatable and standardizable to other metrics of radiotracer uptake. LV%ID is adjusted for injected activity, but not for body weight, because the latter is unnecessary for a radiotracer accumulating in the heart and specific organs, not in the whole body.